REC625-Bivalent Recombinant Respiratory Syncytial Virus Vaccine
REC625-Bivalent Recombinant Respiratory Syncytial Virus Vaccine
REC625–Bivalent Recombinant Respiratory Syncytial Virus Vaccine
The REC625 is equipped with the novel adjuvant independently developed by us and intended to prevent the diseases caused by respiratory syncytial virus infection in the elderly population. Preclinical studies have shown that REC625 has favorable immunogenicity compared to overseas marketed products and can induce high levels of specific neutralizing antibodies, and significantly improve the neutralizing antibodies against subtype B. The project adopted our independently designed vaccine antigen structure and relevant invention patent application has been submitted. We plan to complete the preclinical study for this product in 2025.
